Scarica l'app Stockscreener
33.35
0.42%
0.14
Pre-mercato:
33.47
0.12
+0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRMY Giù?
Forum
Previsione
Precedente Chiudi:
$33.21
Aprire:
$33.77
Volume 24 ore:
307.07K
Relative Volume:
0.51
Capitalizzazione di mercato:
$1.91B
Reddito:
$681.88M
Utile/perdita netta:
$122.63M
Rapporto P/E:
15.81
EPS:
2.11
Flusso di cassa netto:
$220.18M
1 W Prestazione:
-4.44%
1M Prestazione:
+1.83%
6M Prestazione:
-14.77%
1 anno Prestazione:
-0.51%
Intervallo 1D:
$32.86
$33.77
Intervallo di 1 settimana:
$32.85
$35.99
Portata 52W:
$28.14
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Nome
Harmony Biosciences Holdings Inc
Settore
Industria
Telefono
(484) 539-9800
Indirizzo
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Confronta HRMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
33.35 | 1.91B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-10 | Iniziato | UBS | Buy |
| 2024-06-21 | Iniziato | Citigroup | Buy |
| 2024-01-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Downgrade | Goldman | Neutral → Sell |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-20 | Iniziato | BofA Securities | Neutral |
| 2022-10-14 | Aggiornamento | Janney | Neutral → Buy |
| 2022-10-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-04 | Iniziato | Raymond James | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-03-29 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-14 | Iniziato | Goldman | Neutral |
| 2020-09-14 | Iniziato | Jefferies | Buy |
| 2020-09-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Swiss National Bank - Defense World
Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Is Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference - Yahoo Finance
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by PNC Financial Services Group Inc. - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Investors to Inquire about Securities Investigation - Markets Insider
Harmony Biosciences names new chief commercial officer By Investing.com - Investing.com Australia
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer (HRMY:NASDAQ) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Reach Out - Markets Insider
Harmony Biosciences: A Compelling Risk-Reward Opportunity (NASDAQ:HRMY) - Seeking Alpha
Harmony Biosciences names new chief commercial officer - Investing.com India
Harmony Biosciences Names Adam Zaeske As Chief Commercial Officer -March 24, 2025 at 08:25 am EDT - Marketscreener.com
Harmony Biosciences price target raised to $44 from $42 at Mizuho - MSN
Pharma Leader Who Managed $2B Portfolio Joins Harmony Biosciences as Growth Accelerates - StockTitan
HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Charles Schwab Investment Management Inc. Purchases 100,586 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
(HRMY) On The My Stocks Page - Stock Traders Daily
Amundi Acquires 13,041 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
HRMY Down 10.8% In Six Months: How Should You Play The Stock? - Barchart
HRMY Down 10.8% in Six Months: How Should You Play the Stock? - Nasdaq
Mizuho Issues Positive Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price - Defense World
HRMY Crosses Above Key Moving Average Level - Nasdaq
Expert Outlook: Harmony Biosciences Hldgs Through The Eyes Of 11 Analysts - Benzinga
Mizuho lifts Harmony Biosciences stock target to $44 - Investing.com India
Mizuho lifts Harmony Biosciences stock target to $44 By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harmony Biosciences Holdings, Inc.HRMY - PR Newswire
Mizuho Adjusts PT on Harmony Biosciences Holdings to $44 From $42, Maintains Outperform Rating - Marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $44 at Mizuho - StreetInsider.com
Victory Capital Management Inc. Has $5.05 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Bank of New York Mellon Corp - Defense World
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Harmony Biosciences at Leerink Conference: Expanding Horizons in Rare Disorders - Investing.com UK
Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Repor - GuruFocus.com
Proficio Capital Partners LLC Buys New Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences to Present at Upcoming Global Healthcare Conferences - MSN
Harmony Biosciences Holdings, Inc. (HRMY): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - MSN
Lost Money on Harmony Biosciences Holdings, Inc.(HRMY)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - ACCESS Newswire
Amalgamated Bank Buys 2,074 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by Principal Financial Group Inc. - Defense World
Equities Analysts Set Expectations for HRMY FY2025 Earnings - Defense World
Harmony Biosciences Reports Record 2024 Revenue, Targets Billion-Dollar Milestone in 2025 - MyChesCo
HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money - ACCESS Newswire
Harmony Biosciences Faces Regulatory Setback, Outlines Future Plans for Pitolisant - MSN
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Rhumbline Advisers Buys 16,537 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World
Harmony Biosciences (NASDAQ:HRMY) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Denali Advisors LLC - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Harmony Biosciences Holdings Inc Azioni (HRMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.46%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):